

The background is a composite image. On the left, there are several jellyfish in shades of blue, purple, and pink, with their tentacles visible. On the right, there are vertical laboratory glassware items, including test tubes and vials, some containing colored liquids (red, blue, green). The overall aesthetic is scientific and modern.

# Bricco

43<sup>RD</sup> ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

—  
JANUARY 15, 2025

MARIA FORSS, PRESIDENT & CEO

## DISCLAIMER

You must read the following before continuing. The following applies to this document and the information provided in this presentation by BICO AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.

The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not

for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or

affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and of the Company's products, ongoing research and development, the ability to commercialize the Company's products, technology changes and new products in the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future, and although the Company bases these statements on assumptions that it believe to be reasonable when made, these forward-looking statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.



## **Vision**

**BICO enables and  
automates the life science  
lab of the future**

## **Mission**

**Be the first-choice lab  
automation partner  
and provider of  
selected workflows to  
pharma and biotech**





65+

Global Presence  
No of Markets



710+

Employees



11

Companies

# BICO in Figures

Founded in 2016



SEK 2.2bn

Net Sales  
FY 2023




46,000+

Installed Instruments




12,000+

Publications




# FY 2022, FY 2023 and R12M Q3 24: Sales, Adjusted EBITDA and Cash Flow from Operating Activities


Total Sales



Adjusted EBITDA



Operational cash flow



**Be the First-choice Lab Automation Partner  
and Provider of Selected Workflows  
to Pharma and Biotech**


**LAB AUTOMATION**

**LIFE SCIENCE  
SOLUTIONS**

**BIOPRINTING**



# BICO Offers Solutions Predominantly in Molecular Biology, Drug Discovery and Synthetic Biology



BICO focuses on the first three life science value chain steps

Value chain

1 Basic research & discovery

2 Drug & diagnostic development

3 (Bio)-production

4 Clinical use

BICO's current strengths and technologies are largely grouped into three fields

Key BICO fields


Molecular biology

Drug discovery


Synthetic biology



## Basic Research



## Applied Research



# BICO Workflow Landscape





# Strong Customer Base and Relationships in Top Pharma\*

## Pharma & Biopharma

Novo Nordisk AstraZeneca Eli Lilly  
EMD Sereno Astellas Merck KGaA  
Pfizer BMS Roche J&J  
Boehringer Ingelheim MedImmune  
Novartis Genentech BioNTech  
BioMarin AbbVie Amgen  
Sanofi Gilead Regeneron

## Biotech

Cellino DeepCure  
Scribe Therapeutics  
Metagenomi  
Arpeggio Invitae

## Diagnostics

Charles River  
Laboratories

## Cosmetics

Estée Lauder

## Academia & Research


Stanford Harvard  
NIH Max Planck Yale  
UCLA Cambridge  
Oxford MIT Duke  
Karolinska

## Food & Agriculture

Unilever  
Colgate  
Procter & Gamble



# BICO Address Needs Holistically Through End-to-End Workflows



# Key Trends for BICO

- Growing demand for **integrated and automated workflows** in labs for higher efficiency and throughput
- Advanced **data and AI integration**
- Technologies for **rapid compound screening** and hit to lead generation
- Increased focus on **personalized and regenerative medicine**
- **Growing adoption of in-vitro testing** instead of animal testing\*
- **Regulatory compliant platforms**


\* FDA modernization Act and EURL ECVAM



# Total and Serviceable Addressable Market

**Global TAM** (by market segment, 2023, USDbn)


*Potential market size, independently from BICO's ability to reach and serve it*



**Global SAM** (by 2023, USDbn)

*Market size based on customers BICO can serve with existing business*

**Total ~3bn, average CAGR: +12%**




# Lab Automation Industry Evolving significantly

- Market size valued around USD 5.5-6.8bn in 2023
- Growth rate indicated at CAGR 6.3-9.3% in 2023 to 2035
- Integrated automated solutions market we estimate to USD 1.1-1.3 bn and expected to continue to grow faster than the overall lab automation market

Source: Market reports (Portfolio TAM project); Root Analysis, World Industry News, Global Market Insight, Precedence Research, Meticulous Research, Spherical Insights and Insight Lace Analytics. Company analysis.



# Lab Automation and Selected Workflows are the Cornerstones in BICO's Offering



# Updated Strategy BICO 2.0 – Strong Commercial Focus

## Drive Commercial Excellence

Enable  
End-to-End  
**Lab automation**

Further develop  
integrated  
**data, AI and SW  
solutions**

Ensure  
**Regulatory  
Compliance**  
Readiness

Provide Scientific  
**Workflow  
Solutions**

**Increase  
recurring  
revenue**



## The Problem

**Discovering new drugs and marketable scientific innovations**

- Takes years of time
- Cost millions to billions of dollars
- May be heavily regulated

## The BICO Solution

**Accelerating scientific research through automation**





# Laboratory Automation: The breadth of Solutions



MANUAL




SEMI-AUTOMATED



AUTOMATED



FULLY-AUTOMATED



INTEGRATED

Connecting equipment  
through Biosero's  
Green Button Go<sup>®</sup>  
Software



# The Impact of Automation



Reduce downstream process and assay development by up to 75%



Increase existing equipment capacity to develop biopharmaceutical manufacturing processes by 400%



Maximize productivity of development scientists and labs by a minimum of 200%



# BICO Leads the Way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency

## Speed

- Reducing the time to find optimal candidates for treatment therapies

## Accuracy

- Driving forward a personalized approach in treatment
- Enabling the development of physiologically relevant models

## Efficiency

- Maximize productivity of automated laboratory equipment and scientists



# BICO Vision and Strategic Agenda

Vision

BICO ENABLES AND AUTOMATES  
THE LIFE SCIENCE LAB OF THE FUTURE

Mission

Be the **first-choice lab automation partner** and provider of **selected workflows** to pharma and biotech

Strategic  
focus  
areas

Enable end-to-end  
lab automation



Further develop  
integrated data,  
AI and software  
solutions



Ensure **regulatory**  
compliance  
readiness



Provide scientific  
workflow solutions



Increase  
recurring revenue



Values

Trust

Focus

Collaboration

Grit

Impact

Speed and quality through  
automated technology

Efficiency in drug  
development

Tools to accelerate  
personalized medicine

Alternatives to  
animal testing

Financial  
Targets

Double-digit organic growth  
in constant currency

EBITDA margin less capitalized  
development cost > 10%

Net Debt to EBITDA < 3.0x





**Bricco**